Triple-targeted drug therapy for treatment-naive patients with arterial pulmonary hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective, observational study investigates the efficacy and safety of a triple-targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The study aims to gather real-world data on the prognosis of these patients while they are treated with a combination of endothelin receptor antagonists, PDE5 inhibitors, and prostacyclin drugs. By focusing on treatment-naive patients, the study seeks to provide insights into the effectiveness of this therapeutic approach in a clinical setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Consent and sign the informed consent form
* Non-low-risk PAH treatment-naive patients

Exclusion Criteria:

* Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension
* Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary
* Pregnant or lactating women
* Suffering from mental illness or cognitive impairment
* PAH patients with concurrent malignant tumors
* Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia
* Currently participating in other interventional clinical studies
* Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.

Where it's running

• Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Guanghai Wang, Prof.
• Email: 224138908@qq.com
• Phone: +86 18553136966

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sleep problems in PAH patients: how sleep breathing relates to PAH outcomes

  This study tests how sleep-disordered breathing and nocturnal oxygen changes relate to outcomes in adults with pulmonary arterial hypertension.

  Recruiting Chinese Pulmonary Vascular Disease Research Group · Beijing · NCT07852403

• Impact of ambient air vs nasal liquid oxygen on exercise performance in pulmonary vascular disease

  This study tests whether using nasal liquid oxygen during a 6-minute walk test changes how far patients with PAH or CTEPH can walk compared to breathing room air.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777445

• Liquid oxygen vs ambient air during a 6-minute walk in people with pulmonary vascular disease

  This study tests whether walking with liquid oxygen at about 4 L/min helps or hinders distance walked compared with walking on room air in adults with PAH or CTEPH living in Switzerland.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777367

• Treprostinil inhalation powder for PAH patients switching from selexipag

  This study tests whether inhaled treprostinil (LIQ861) is safe and tolerable for adults with PAH who are moving from oral selexipag to inhaled therapy.

  Recruiting Phase 4 Liquidia Technologies, Inc. · Columbus, Georgia · NCT07759804

• Escalation options for PAH patients already on dual therapy

  This trial tests whether adding a prostacyclin pathway drug or increasing sildenafil dose helps PAH patients at intermediate-to-high risk who aren’t at low risk despite dual therapy.

  Recruiting Phase 4 University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07713914

• Vasoactive Agents in Pulmonary Hypertension Crisis

  This trial tests whether dopamine, norepinephrine, or epinephrine can safely and effectively help people with a pulmonary hypertension crisis who are in the hospital.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality and 2 other locations · NCT07667829

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.